Furthermore, the short isoform behaved as a putative tumor suppressor based on cell proliferation and cell colony formation assays. 
THERM
The Short Isoform of Nuclear Mitotic Apparatus Protein 1 Functions as a Putative Tumor Suppressor.BACKGROUND
 Nuclear mitotic apparatus protein 1 (NuMA1) had been reported to produce three groups of isoforms categorized as long, middle, and short groups, of which short NuMA displayed distinct localization patterns compared to long and middle isoforms.  However, the function of short NuMA was not clear in the progress of cancer formation.  This study aimed to unveil the role of short NuMA in cancer pathogenesis.


 The expression levels of short isoforms were explored in paired gastric carcinoma (GC) samples and different cell lines.  Furthermore, the short isoform behaved as a putative tumor suppressor based on cell proliferation and cell colony formation assays.  Pull-down assay and whole-genome gene expression analysis were carried out to search candidate interaction partners of short NuMA.


 The expression of short NuMA was highly expressed in S and G2 phases of the cell cycle; compared with nontumor tissues, short NuMA downregulated in nine GCs (GC1 [0.131, P = 5 × 10-4]; GC2 [0.316, P = 3 × 10-5]; GC3 [0.111, P = 6 × 10-4]; GC4 [0.456, P = 0.011]; GC5 [0.474, P = 0.001]; GC6 [0.311, P = 0.004]; GC7 [0.28, P = 3 × 10-5]; GC8 [0.298, P = 0.007]; and GC9 [0.344, P = 0.002]).  Besides, high expression of short NuMA significantly inhibits cell growth (2.43 × 105 vs. 2.97 × 105, P = 0.0029) and cell clone information in vitro (70 vs. 2, P = 1.67 × 10-45).  Short NuMA could bind with alpha-actinin-4 (ACTN4), a putative tumor promoting gene.  Overexpression of short NuMA could tremendously decrease the expression of MYB proto-oncogene like 2 (MYBL2) of about 92-fold, which played an important role in the cell cycles.


 CONCLUSIONS
 Short isoform of NuMA might be functioned as a putative role of tumor suppressor.  Further studies should be made to illuminate the relationship between ACTN4, MYBL2, and tumor progression.
C